Author

J. Iyyathurai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Assay:metagenomics· 1 Organism:virus· 1

Frequent Co-Authors

A. Kensiski· 1 shared B. Bai· 1 shared B. Ma· 1 shared C. Paluskievicz· 1 shared D. Hoagland· 1 shared E. Arutyunova· 1 shared E. F. Mongodin· 1 shared E. Moussa· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Kensiski

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals

S. A. Chen, E. Arutyunova, J. Lu, M. B. Khan, W. Rut, M. Zmudzinski, S. Shahbaz, J. Iyyathurai, E. Moussa, Z. Turner, B. Bai, T. Lamer, J. A. Nieman, J. C. Vederas, O. Julien, , M. J. Lemieux

The paper examines how SARS-CoV-2 Mpro variants affect viral and host protein processing but maintain antiviral potency.

bioRxiv · Jan 28, 2023 · PreprintBiochemistry

Early immunomodulatory program triggered by pro-tolerogenic Bifidobacterium pseudolongum drives cardiac transplant outcomes

S. J. Gavzy, A. Kensiski, V. Saxena, R. Lakhan, L. Hittle, L. Wu, J. Iyyathurai, H. Dhakal, Z. L. Lee, L. Li, Y. Lee, T. Zhang, H. W. Lwin, M. W. Shirkey, C. Paluskievicz, , J. S. Bromberg

This study identifies Bifidobacterium pseudolongum as inducing an early anti-inflammatory response that influences cardiac transplant outcomes.

bioRxiv · Oct 13, 2022 · PreprintImmunology

Targeting the Cx43 Carboxyl Terminal H2 Domain Preserves Left Ventricular Function Following Ischemia-Reperfusion Injury

J. Jiang, J. A. Palatinus, H. He, J. Iyyathurai, J. L. Jourdan, D. Hoagland, G. Bultynck, Z. Wang, Z. Zhang, K. Schey, S. Poelzing, F. X. McGowan, R. G. Gourdie

This paper identifies that CT1's interaction with Cx43's carboxyl terminal H2 domain, not ZO-1, mediates its protective effects against ischemia-reperfusion injury in the heart.

bioRxiv · Jun 12, 2019 · PreprintCell Biology